Although CGRP McAb seems to be safe, in routine clinical practice, a 41-year-old woman with non-aura migraine developed right thalamic infarction after taking the first dose of CGRP McAb (Aradi et al., 2019); and clinically, a migraine patient treated with CGRP McAb developed reversible cerebral vasoconstriction syndrome (Rozen and Bhatt, 2022). The gene discussed is CALCA; the disease is migraine disorder.